Sign In
Buy BBIO
$80.09
-2.05 (-2.50%)
At Close: Jul 31, 2026
Ten large-cap stocks sank last week as weak earnings, lowered guidance, analyst downgrades, and deal-related headlines weighed on shares.
Randal Scott Sells 10,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
06:38am, Friday, 20'th Feb 2026
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) Director Randal Scott sold 10,000 shares of the company's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold a
BIT Capital GmbH Reduces Holdings in BridgeBio Pharma, Inc. $BBIO
06:38am, Friday, 20'th Feb 2026
BIT Capital GmbH cut its position in BridgeBio Pharma, Inc. (NASDAQ: BBIO) by 94.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commis
Thomas Trimarchi Sells 13,600 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
06:38am, Friday, 20'th Feb 2026
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CFO Thomas Trimarchi sold 13,600 shares of the company's stock in a transaction on Tuesday, February 17th. The stock was sold at an average pric
Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO
03:32am, Thursday, 19'th Feb 2026
Oppenheimer and Co. Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor ac
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06:22pm, Tuesday, 17'th Feb 2026
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
07:30am, Tuesday, 17'th Feb 2026
PALO ALTO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genet
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,877,600.00 in Stock
04:54am, Sunday, 15'th Feb 2026
BridgeBio Pharma, Inc. (NASDAQ: BBIO - Get Free Report) CEO Neil Kumar sold 40,000 shares of the company's stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price o
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
05:54pm, Thursday, 12'th Feb 2026
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma shares rise on ‘compelling' Phase 3 trial results for achondroplasia drug
03:51pm, Thursday, 12'th Feb 2026
BridgeBio Pharma (NASDAQ:BBIO) saw its shares rise more than 5% to about $77 on Thursday after reporting positive Phase 3 topline results for oral infigratinib in achondroplasia, with Jefferies analys
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
11:05am, Thursday, 12'th Feb 2026
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug
10:47am, Thursday, 12'th Feb 2026
BridgeBio Pharma (NASDAQ:BBIO) saw its shares rise more than 5% to about $77 on Thursday after reporting positive Phase 3 topline results for oral...
BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug
07:30am, Thursday, 12'th Feb 2026
BridgeBio unveiled promising results Thursday for its "hotly debated" final-phase asset: a potential treatment for achondroplasia.
- PROPEL 3 successfully met the primary endpoint of change from baseline in AHV at Week 52 (p
Baader Bank Aktiengesellschaft Takes Position in BridgeBio Pharma, Inc. $BBIO
05:22am, Thursday, 12'th Feb 2026
Baader Bank Aktiengesellschaft acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) in the undefined quarter, according to its most recent disclosure with the Securities and Exch
